Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Glycine, N-(6-((((4-(1h-pyrazol-1-yl)phenyl)methyl)(3-pyridinylsulfonyl)amino)methyl)-2-pyridinyl)-, 1-methylethyl Ester
2. Isopropyl N-(6-(((4-(1h-pyrazol-1-yl)benzyl)(3-pyridinylsulfonyl)amino)methyl)-2-pyridinyl)glycinate
1. 1187451-19-9
2. De-117
3. Omidenepag Isopropyl [usan]
4. G0g0h52u6k
5. Propan-2-yl N-(6-((n-((4-(1h-pyrazol-1-yl)phenyl)methyl)pyridine-3-sulfonamido)methyl)pyridin-2-yl)glycinate
6. Omidenepag Isopropyl (jan)
7. Omidenepag Isopropyl [jan]
8. Glycine, N-(6-((((4-(1h-pyrazol-1-yl)phenyl)methyl)(3-pyridinylsulfonyl)amino)methyl)-2-pyridinyl)-, 1-methylethyl Ester
9. Glycine, N-[6-[[[[4-(1h-pyrazol-1-yl)phenyl]methyl](3-pyridinylsulfonyl)amino]methyl]-2-pyridinyl]-, 1-methylethyl Ester
10. Eybelis (tn)
11. Unii-g0g0h52u6k
12. Chembl4297666
13. Schembl15414827
14. Tqr1222
15. Dtxsid001106409
16. Bcp26206
17. Ex-a4371
18. Bdbm50506549
19. Omidenepag Isopropyl [who-dd]
20. At36244
21. Db15071
22. Sb18739
23. Hy-111406
24. Cs-0040499
25. Omdi;de-117; De 117; De117
26. D10966
27. Q27896252
28. Isopropyl 2-((6-((n-(4-(1h-pyrazol-1-yl)benzyl)pyridine-3-sulfonamido)methyl)pyridin-2-yl)amino)acetate
29. N-[6-[[[[4-(1h-pyrazol-1-yl)phenyl]methyl](3-pyridinylsulfonyl)amino]methyl]-2-pyridinyl]glycine 1-methylethyl Ester
30. Propan-2-yl 2-[[6-[[(4-pyrazol-1-ylphenyl)methyl-pyridin-3-ylsulfonylamino]methyl]pyridin-2-yl]amino]acetate
| Molecular Weight | 520.6 g/mol |
|---|---|
| Molecular Formula | C26H28N6O4S |
| XLogP3 | 3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 12 |
| Exact Mass | 520.18927457 g/mol |
| Monoisotopic Mass | 520.18927457 g/mol |
| Topological Polar Surface Area | 128 Ų |
| Heavy Atom Count | 37 |
| Formal Charge | 0 |
| Complexity | 814 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
API SUPPLIERS
Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34079
Submission : 2020-01-21
Status : Active
Type : II
Registration Number : 229MF10105
Registrant's Address : 3-3-23 Nakanoshima, Kita-ku, Osaka City, Osaka Prefecture
Initial Date of Registration : 2017-06-21
Latest Date of Registration : --
NDC Package Code : 12848-1006
Start Marketing Date : 2022-12-19
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (0.1kg/.1kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Korea Santen Pharmaceutical Co., Ltd.
Registration Date : 2019-12-03
Registration Number : 4272-4-ND
Manufacturer Name : Asahi Kasei Finechem Co., Ltd. Nobeoka Pharmaceuticals Plant
Manufacturer Address : 6-2633-7 Asahi-machi, Nobeoka City, Miyazaki, Japan
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
Through the merger, Ocuvex will boast a robust pipeline of ophthalmic medicines, which includes Omlonti (omidenepag isopropyl), indicated for the treatment of open-angle glaucoma.
Lead Product(s): Omidenepag Isopropyl
Therapeutic Area: Ophthalmology Brand Name: Omlonti
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Ocuvex Therpeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger August 19, 2024
Lead Product(s) : Omidenepag Isopropyl
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Ocuvex Therpeutics
Deal Size : Undisclosed
Deal Type : Merger
Visiox Pharmaceuticals, Inc. Announces Transformative Merger with Ocuvex Therpeutics, Inc.
Details : Through the merger, Ocuvex will boast a robust pipeline of ophthalmic medicines, which includes Omlonti (omidenepag isopropyl), indicated for the treatment of open-angle glaucoma.
Brand Name : Omlonti
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 19, 2024
Details:
Under the agreement, Visiox gain rights to product manufacturing, commercialization, and sales of Omlonti (omidenepag isopropyl), an eye drop for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Lead Product(s): Omidenepag Isopropyl
Therapeutic Area: Ophthalmology Brand Name: Omlonti
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Visiox Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 18, 2023
Lead Product(s) : Omidenepag Isopropyl
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Visiox Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Visiox gain rights to product manufacturing, commercialization, and sales of Omlonti (omidenepag isopropyl), an eye drop for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Brand Name : Omlonti
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 18, 2023
Details:
OMLONTI® (omidenepag isopropyl ophthalmic solution) 0.002%, is a relatively selective prostaglandin E2 (EP2) receptor agonist, indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Lead Product(s): Omidenepag Isopropyl
Therapeutic Area: Ophthalmology Brand Name: Omlonti
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: UBE Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2022
Lead Product(s) : Omidenepag Isopropyl
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : UBE Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
Santen and UBE Received FDA Approval for OMLONTI® (Omidenepag Isopropyl Ophthalmic Solution) 0.00...
Details : OMLONTI® (omidenepag isopropyl ophthalmic solution) 0.002%, is a relatively selective prostaglandin E2 (EP2) receptor agonist, indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension...
Brand Name : Omlonti
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 26, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
